Smoking is a leading cause of preventable death, causing about 5 million premature deaths worldwide each year 1,2 . Evidence for genetic influence on smoking behaviour and nicotine dependence (ND) 3-8 has prompted a search for susceptibility genes. Furthermore, assessing the impact of sequence variants on smokingrelated diseases is important to public health 9,10 . Smoking is the major risk factor for lung cancer (LC) [11] [12] [13] [14] and is one of the main risk factors for peripheral arterial disease (PAD) [15] [16] [17] . Here we identify a common variant in the nicotinic acetylcholine receptor gene cluster on chromosome 15q24 with an effect on smoking quantity, ND and the risk of two smoking-related diseases in populations of European descent. The variant has an effect on the number of cigarettes smoked per day in our sample of smokers. The same variant was associated with ND in a previous genomewide association study that used low-quantity smokers as controls 18, 19 , and with a similar approach we observe a highly significant association with ND. A comparison of cases of LC and PAD with population controls each showed that the variant confers risk of LC and PAD. The findings provide a case study of a gene-environment interaction 20 , highlighting the role of nicotine addiction in the pathology of other serious diseases.
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Smoking is a leading cause of preventable death, causing about 5 million premature deaths worldwide each year 1, 2 . Evidence for genetic influence on smoking behaviour and nicotine dependence (ND) [3] [4] [5] [6] [7] [8] has prompted a search for susceptibility genes. Furthermore, assessing the impact of sequence variants on smokingrelated diseases is important to public health 9, 10 . Smoking is the major risk factor for lung cancer (LC) [11] [12] [13] [14] and is one of the main risk factors for peripheral arterial disease (PAD) [15] [16] [17] . Here we identify a common variant in the nicotinic acetylcholine receptor gene cluster on chromosome 15q24 with an effect on smoking quantity, ND and the risk of two smoking-related diseases in populations of European descent. The variant has an effect on the number of cigarettes smoked per day in our sample of smokers. The same variant was associated with ND in a previous genomewide association study that used low-quantity smokers as controls 18, 19 , and with a similar approach we observe a highly significant association with ND. A comparison of cases of LC and PAD with population controls each showed that the variant confers risk of LC and PAD. The findings provide a case study of a gene-environment interaction 20 , highlighting the role of nicotine addiction in the pathology of other serious diseases.
To perform a genome-wide association (GWA) study of smoking quantity (SQ), we used questionnaire data limited to basic questions on smoking behaviour that were available for a large number of lifetime smokers. The GWA scan comprises 10,995 Icelandic smokers who had been assayed with Infinium HumanHap300 SNP chips from Illumina. A set of 306,207 single-nucleotide polymorphisms (SNPs) fulfilling our quality criteria was tested. We focused on cigarette smoking, with SQ reported as cigarettes per day. All SQ data were clustered into categories (see Supplementary Information) and we refer to them as 'SQ levels'. The SQ levels were 0 (1-10 cigarettes per day), 1 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , 2 (21-30) and 3 (31 or more). Each increment represents an increase in SQ of 10 cigarettes per day. Allele T of the SNP rs1051730 was most strongly associated with SQ, and the association was highly significant (P 5 5 3 10 216 ). The SNP is within the CHRNA3 gene in a linkage disequilibrium block also containing two other genes, CHRNA5 and CHRNB4, that encode nicotinic acetylcholine receptors (ref. 18) . Six other SNPs on chromosome 15q24 passed the threshold of genome-wide significance (P , 2 3 10 27 ), but they are all correlated with rs1051730 (r 2 5 0.14-0.93). After correction for rs1051730, none of these six SNPs showed a P value below 10
23 (see Supplementary Table 1) . A quantile-quantile plot for the GWA scan (see Supplementary Fig. 1a) shows the observed excess of signals, whereas a quantile-quantile plot after removing 182 markers located within 1 megabase of rs1051730 is consistent with noise (see Supplementary Fig. 1b) , illustrating that all of the strongest signals standing out in the first plot are located on chromosome 15q24. An additional 2,950 smokers from Iceland were genotyped for rs1051730, giving a total of 13,945 smokers (Table 1 ) with a mean variant frequency of 34.7%, which is not significantly different from the frequency of 34.4% observed in 4,203 individuals who were genotyped and who reported never having smoked (odds ratio (OR) 1.01, 95% confidence interval (CI) 0.96-1.07, P 5 0.60). Indeed, the frequency of the variant in the 3,627 low-quantity smokers (10 or fewer cigarettes per day) is significantly less than that in those who do not smoke (OR 0.83, 95% CI 0.78-0.90, P 5 4.5 3 10 frequency between levels varies, and the largest increase (4.5%) is observed between the lowest levels (0 and 1), whereas the increase between the highest levels (2 and 3) is only 1.1%. In the context of a case-control LC study, an additional 523 smokers from Spain and 1,375 smokers from The Netherlands were genotyped. We performed multiple regression analyses of SQ data from the three countries, with adjustment for sex and year of birth ( Table 2) . Results from Spain and The Netherlands combined gave an estimated increase of 0.074 SQ units (P 5 0.012) for each copy of the variant, which is not significantly different (P 5 0.45) from the estimate of 0.098 SQ units (P 5 10
218
) based on the Icelandic data. Combining all results, each copy of the variant was estimated to increase SQ level by 0.095 units (P 5 6 3 10 220 ), which corresponds to about one cigarette per day. A recent GWA study reported an association between SQ and SNP rs6495308 (P 5 6.9 3 10
25
, correlation between this SNP and rs1051730, r 2 5 0.18 in the HapMap project) for about 7,500 individuals from two study groups, as well as association between SQ and rs1317286 (P 5 2.6 3 10
26
, r 2 5 0.90 to rs1051730 in the HapMap project) in a candidate gene study based on 1,740 heavy smokers (more than 25 cigarettes per day) and 6,200 low-quantity smokers (fewer than 5 cigarettes per day) 21 . Sex and year of birth are also strongly associated with SQ (Table 2) . However, neither the interaction between variant and sex nor that between variant and year of birth is significant, indicating that the effect of the variant is similar for both sexes and is robust to population-wide changes in smoking habits over time. The phenotypic variance explained by the variant was highest in Iceland, amounting to 0.7%.
Association of the same variant with ND was previously reported in a candidate gene study involving 3,713 SNPs 18 . We assessed the association with ND, defined as a score of 4 or higher on the Fagerstrom Test for Nicotine Dependence (FTND) 22 or endorsement of at least three of the seven Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) criteria (see Supplementary Information). The variant is associated with ND in Iceland in a subset of 2,394 smokers from the SQ study tested against both 28,455 population controls (OR 1.17, 95% CI 1.10-1.25, P 5 3.3 3 10 26 ) and 3,506 low-quantity smokers (OR 1.40, 95% CI 1.29-1.52, P 5 7 3 10 215 ). The latter OR of 1.40 is comparable to the results of the candidate gene study 18 . They used non-ND smokers as controls (that is, individuals who had smoked but had an FTND score of 0), and reported association with rs1051730 (OR 1.3, P 5 10 23 ). rs1051730 is in strong linkage disequilibrium with rs16969968 (r 2 5 0.90 in the HapMap project), which was highlighted in the previous study with a similar result (OR 1.3, P 5 6 3 10 24   ) 18 .
Dependence on nicotine drives repeated self-administration of nicotine [23] [24] [25] and high SQ is a strong sign of ND and one of the criteria for a diagnosis of ND (SQ is included in the FTND scale). This, together with the fact that the ND subjects are part of the SQ study, means that the associations with ND and SQ cannot be considered independent results. Both the FTND and the DSM-IV scales include many items that are not based on SQ, and their total scores are measures of ND severity. In our ND group, positive scores on most items in both scales show a trend towards higher frequency of the variant, as does the total score on both the FTND and DSM-IV scales. Thus, the frequency of the variant increases with addiction severity, and is 46.8% and 43.8% for the highest deciles of FTND and DSM-IV, respectively (see Supplementary Table 2a , b). ND is believed to be the main reason for continued smoking. To explore the frequency of the variant in the context of the ability to quit smoking, we investigated differences between 6,388 current and 6,687 past smokers from the SQ analysis by a logistic regression model adjusting for sex and year of birth. The variant was associated with current smoking with an OR of 1.07 (95% CI 1.01-1.13, P 5 0.015) (see Supplementary  Table 3) , and the effect is similar when corrected for SQ (OR 1.06, 95% CI 1.00-1.12, P 5 0.036), indicating that carriers of the variant are less likely to quit smoking.
Smoking is a major risk factor for many diseases, and we decided to study the effect of the variant on LC and PAD risk directly. The LC study was based on 1,024 cases and 32,244 controls from Iceland, Spain and The Netherlands (Table 3) ; the PAD study was based on 2,738 cases and 29,964 controls from five caucasian populations (Iceland, New Zealand, Austria, Sweden and Italy) ( Table 3) . The results for LC and PAD (Table 4 ) represent the overall effect on LC and PAD including indirect effects through SQ and ND. Significant association was observed with LC for both the Icelandic data (OR 1.27, P 5 4.1 3 10 25 ) and the data for Spain and The Netherlands combined (OR 1.39, P 5 6.6 3 10 25 ). These two estimates are not significantly different from each other (P 5 0.34), and combining results from all three groups gave an OR of 1.31 (95% CI 1.19-1.44, P 5 1.5 3 10 28 ). There is no significant difference in frequency of the variant between histological types of LC, which is not surprising given the small number of cases per group (see Supplementary  Table 4 ). Association with PAD was found both in the Icelandic data (OR 1.18, P 5 5.3 3 10 25 ) and in the data for the foreign populations combined (OR 1.23, P 5 5.9 3 10 24 ). These two estimates are not significantly different from each other (P 5 0.57), and combining results from all five groups gave an OR of 1.19 (95% CI 1.12-1.27, P 5 1.4 3 10 27 ). Genotypic ORs for LC, PAD and ND did not deviate significantly from those obtained for the multiplicative model (see Supplementary  Table 5) , and no significant differences in the ORs between sexes were observed (see Supplementary Table 6 ).
According to our estimates for Icelandic LC patients, the correlation between SQ and LC is consistent with numbers reported in other studies 26, 27 . Combining these estimates with our estimate of the association of the variant with SQ, the expected OR between the variant and LC is only about 1.05 in Iceland (see Supplementary Information), which is well below the direct OR estimate for LC of 1.27 (95% CI 1.13-1.43). A similar indirect estimate for PAD is 1.04, which again is substantially lower than the observed direct estimate of 1.18 (95% CI 1.09-1.27). It is not surprising that the ORs for LC and PAD cannot be explained by the effect of the variant on SQ alone, because the involvement of both SQ and the duration of smoking in LC and PAD was established in previous studies 15, 28 . The SQ data for most individuals were derived from a single point in time and cannot be expected to cover all aspects of smoking behaviour affected by the variant and relevant to LC and PAD. An effect on other aspects of smoking behaviour, in particular smoking duration, is likely to account for the observed difference between the indirect and direct estimates of the LC and PAD risks. An alternative possibility is that the variant directly confers risk of LC and PAD, for example by increasing the vulnerability to tobacco smoke.
Thus, we have unequivocally demonstrated a correlation between, on the one hand, a sequence variant in the cluster of genes on chromosome 15 that encode nicotinic acetylcholine receptors and, on the other, SQ and ND. The variant does not influence smoking initiation; however, among smokers, carriers of the variant smoke more than non-carriers and have higher rates of ND. This variant was reported in a previous study of 1,050 ND cases and 879 controls who smoked and had an FTND score of 0 (refs 18, 19) and the authors concluded that the variant contributes to ND (ref. 18 ). This conclusion is put on firm ground by the highly significant OR of 1.40 (P 5 7 3 10 215 ) for ND compared with low-quantity smokers (ten or fewer cigarettes per day). The direct measurement of the risk of LC and PAD revealed genome-wide significant associations with allelic ORs of 1.31 and 1.19, respectively. This demonstrates that a sequence variant associated with ND, a brain disorder, confers risk of lung and cardiovascular diseases through an effect on behaviour, which is an example of active gene-environment correlation 20 in the pathogenesis of disease. A calculation of the population attributable risk for the variant gives 18% for LC and 10% for PAD. Although these population attributable risks are at best approximate figures given the complex interplay between the variant, smoking, and smoking-related diseases, it is likely that the variant accounts for a substantial fraction of PAD and LC cases and the associated morbidity and mortality.
The results of the study described here show that it is important to keep in mind, while attempting to shed light on the role of nature versus nurture in the pathogenesis of common or complex disease, that variants in the sequence of our genome influence not only how we respond to our environment but also our tendency to seek or avoid environment. The line between nature and nurture is therefore sometimes conspicuously absent.
METHODS SUMMARY
Subjects. Written informed consent was obtained from all subjects in the seven participating populations (Iceland, Spain, The Netherlands, Sweden, Italy, Austria and New Zealand; see Table 3 ). Inclusion in the study required the availability of genotypes from either GWA studies performed at deCODE genetics or follow-up genotyping of rs1051730 in additional subjects. All subjects were of European descent. For details on recruitment periods and diagnostic criteria used for the ND, LC and PAD groups, see Methods and Supplementary Information. Association analysis. For the genome-wide study of SQ the significance threshold was set at 2 3 10
27
, which is about 0.05 divided by 306,207, the number of SNPs passing quality control. Regressing SQ level as a quantitative variable on the number of copies of the allele carried (0/1/2), a likelihood ratio x 2 statistic was used for testing. Evaluation of statistical significance took the relatedness of the individuals into account by dividing the x 2 statistic by a correction factor based either on the method of genomic control 29 or on a simulation procedure using the known genealogy that we had previously employed 30 (see Supplementary Information). The variant did not correlate with sex or year of birth in the controls; the association analyses were therefore not adjusted for these factors. ORs were assumed to have log-normal distributions, and the confidence intervals are test-based.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
